Compare VIR & PLSE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | VIR | PLSE |
|---|---|---|
| Founded | 2016 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medical/Dental Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 825.0M | 1.2B |
| IPO Year | 2019 | 2016 |
| Metric | VIR | PLSE |
|---|---|---|
| Price | $5.99 | $13.71 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 11 | 1 |
| Target Price | ★ $25.73 | $22.00 |
| AVG Volume (30 Days) | ★ 1.9M | 188.7K |
| Earning Date | 11-05-2025 | 11-05-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $16,860,000.00 | $86,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $46.25 | $1,002.94 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $4.16 | $12.56 |
| 52 Week High | $14.45 | $25.00 |
| Indicator | VIR | PLSE |
|---|---|---|
| Relative Strength Index (RSI) | 48.15 | 43.01 |
| Support Level | $5.76 | $14.33 |
| Resistance Level | $6.12 | $14.91 |
| Average True Range (ATR) | 0.32 | 0.74 |
| MACD | -0.06 | 0.01 |
| Stochastic Oscillator | 22.18 | 14.15 |
Vir Biotechnology Inc is an immunology company focused on combining cutting-edge technologies to treat and prevent serious infectious diseases and other serious conditions, including viral-associated diseases. Through internal development, collaborations, and acquisitions, it has four technology platforms, focused on antibodies, T cells, innate immunity, and small interfering ribonucleic acid, or siRNA. The company's pipeline consists of product candidates targeting hepatitis B, HBV, influenza A, human immunodeficiency virus, HIV, and tuberculosis, or TB. Its revenue sources are collaboration revenue, contract revenue, grant revenue, and license revenue.
Pulse Biosciences Inc is a novel bioelectric medicine company committed to health innovation using its patented Nano-Pulse Stimulation technology, a revolutionary energy modality that delivers nanosecond-duration pulses of electrical energy, each less than a millionth of a second long, to non-thermally clear targeted cells while sparing adjacent noncellular tissue. NPS technology, also referred to as Nanosecond Pulsed-Field Ablation or nsPFA technology when used to ablate cellular tissue, can be used to treat a variety of medical conditions for which an optimal solution remains unfulfilled.